Press

  • EpiVax Launches Precision Immunotherapy Venture

    Posted on September 25, 2017 by Annie De Groot
    EpiVax Oncology Press Release Sept 25 2017 Sept 25, 2017 (Providence, RI) – EpiVax, Inc., a leader in the fields of immunogenicity assessment, vaccine design, and immune-engineering today announced the launch of EpiVax Oncology Inc., a company focused on the development of personalized therapeutic cancer vaccines. EpiVax has provided $500,000 in seed funding and has provided ...
    Read more
  • EpiVax Awarded Grant For Vaccine Engineering

    Posted on September 17, 2017 by Steven Vessella
    $5.8 MILLION AWARDED FOR VACCINE ENGINEERING WILL USE “IMMUNE HISTORY” TO PROTECT AGAINST BIRD FLU, A COLLABORATION LED BY EPIVAX   PROVIDENCE, R.I., Sept. 18, 2017– EpiVax, Inc. (“EpiVax”) a pioneer in the fields of bioinformatics and immune engineering, today announced a new NIH-funded collaboration to develop a protective avian influenza A (H7N9) vaccine. H7N9 is distantly related to seasonal influenza ...
    Read more
  • EpiVax and EpiVax Oncology: Ready to Take on Cancer

    Posted on August 22, 2017 by Katie Porter
    EpiVax has carved out a niche in the biotech and immunoinformatics industry with our innovative tools and discoveries. Well-situated on a trajectory Dr. De Groot described as “upward and stable,” EpiVax is now gearing up to launch a venture-backed spinoff called EpiVax Oncology. EpiVax Oncology Inc. is a newly created, wholly owned subsidiary of EpiVax Inc. ...
    Read more
  • EpiVax – Best Place to Work 2017!

    Posted on August 3, 2017 by Annie De Groot
      2017 Winner of Best Places to Work (Small and Medium Companies) We’re proud and we like to show it ! 
    Read more
  • EpiVax Awarded New “Innovation Voucher”

    Posted on August 3, 2017 by epivax3
    Accelerating the Development of a Game Changing Cancer Therapy PROVIDENCE, R.I., Aug. 3, 2017 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today announced it received funding from the Rhode Island Commerce Corporation to accelerate the development of personalized cancer vaccines using in silico methods. In partnership with Rhode Island Hospital, EpiVax’s innovative project aims to identify cancer-specific targets, or neoantigens, capable of directing ...
    Read more
  • Optimized H7N9 induces higher Ab in humanized, but not standard, mice

    Posted on May 24, 2017 by Annie De Groot
      A new article in Nature Scientific Reports (doi: 10.1038/s41598-017-01372-5) entitled A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines may explain why H7N9 influenza vaccines are consistently less immunogenic in humans than vaccines developed for other subtypes of influenza. In previous work, we identified a key T-cell epitope in H7 hemagglutinin (HA) that ...
    Read more
  • Happy Birthday EpiVax! We’re Celebrating With a New Look!

    Posted on May 18, 2017 by Katie Porter
    Nineteen years ago, on May 18th, 1998, EpiVax incorporated as a biotechnology company. In 2017, our business has never been stronger: the team is stacked with talent, collaborations are abundant and world-wide, and our in silico user base is extensive. We were recently recognized as one of the 2017 Best Places to Work in Rhode Island, we are ...
    Read more
  • Tregitope Takes a Step Toward the Clinic

    Posted on April 25, 2017 by Steven Vessella
    EpiVax Signs First Commercial License for Tregitope Technology   PROVIDENCE, R.I., April 25, 2017 – Providence-based biotechnology company EpiVax, Inc. (“EpiVax”) has licensed its novel immune-modulating technology to an undisclosed global pharmaceutical company, for use in autoimmune disease and allergy. Tregitopes, pronounced T·rej·itopes, are a set of peptides first discovered in human immunoglobulin by EpiVax CEO Annie De Groot and EpiVax CIO Bill Martin. ...
    Read more
  • BARDA, WHO, CDC and H7N9: Doing the Same Thing All Over Again?

    Posted on March 7, 2017 by Annie De Groot
    “Insanity: doing the same thing over and over again and expecting different results.” – Albert Einstein. Due to its high rate of lethality (30-40%) and pandemic potential, H7N9 preparedness has become a priority for public health officials. While mutations that would enable human to human transmission by the avian strain have not yet occurred, CDC placed H7N9 at the ...
    Read more
  • 5th Annual NTD/EID Workshop

    Posted on February 20, 2017 by Annie De Groot
    5th Annual NTD/EID Computational Vaccinology Workshop May 15th – 19th, 2017 iCubed, 80 Washington Street  Providence RI, United States   The Institute for Immunology and Informatics (iCubed) will once again be hosting our training workshop in vaccine design for Neglected Tropical Diseases and Emerging Infectious Diseases (NTD/EID) This May, the Institute for Immunology and Informatics (iCubed) will once again be hosting a training workshop in ...
    Read more
  • EpiVax at Bio Asia 2017

    Posted on February 20, 2017 by Annie De Groot
    Lucky us! the 14th International Bio Asia Conference is scheduled for March 14-15, 2017 at the Grand Hyatt, Tokyo in Roppongi. It might be a bit early for cherry blossoms, but hope springs eternal! We will be arriving a bit early and staying a bit late. Please let us know if you would like us to meet with you ...
    Read more
  • Our Prediction for 2017: Out with Post Hoc and Go DeFT! 

    Posted on February 10, 2017 by Katie Porter
    It’s a new year and welcome to it! Pundits are making a lot of predictions about the decline of science and technology under the new administration in Washington DC, and I’m here with a contrarian view. We bet on biotechnology! We predict that the next four years will see a revolution and acceleration of innovation, regardless of ...
    Read more
  • Will EpiVax Tools be the Ancer to Cancer?

    Posted on January 2, 2017 by Annie De Groot
    EpiVax Oncology – New Year, New Endeavor! A nice story in ConvergenceRI that describes the rapid growth of EpiVax and our decision to invest in a new spin-out company in 2017: Welcome EpiVax Oncology! Annie was interviewed by Richard Asinof about “EpiVax Oncology” in the Epibar: link to the full story here, and read more about the ...
    Read more
  • tularemia bacteria

    $1.87M BioDefense Grant to EpiVax and CUBRC

    Posted on December 19, 2016 by Annie De Groot
    CUBRC and EpiVax Awarded DTRA Grant worth $1.87 Million to Perform Research into Vaccine Antigen Design for Burkholderia pseudomallei Buffalo, NY – December 19, 2017 – CUBRC, Inc.’s President and CEO, Tom McMahon, announced today that CUBRC’s Biological and Medical Sciences team, in collaboration with EpiVax, Inc., has received a four-year grant worth $1.87 million from ...
    Read more
  • The Ancer to Cancer: A computational pipeline for personalized cancer vaccine design

    Posted on December 11, 2016 by Annie De Groot
    Building on 18 years of commercially successful research and development in the field of computational immunology, EpiVax has now developed Ancer™, a personalized cancer vaccine platform. Ancer is a high-speed, secure, cloud-based commercial platform for processing cancer/normal protein sets, identifying high-quality patient-specific neo-antigens, and designing personalized cancer vaccines. EpiVax has established a reputation for innovative cloud-based ...
    Read more